[Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers]

Dtsch Med Wochenschr. 2004 Apr 8;129(15):831-5. doi: 10.1055/s-2004-823030.
[Article in German]
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenergic alpha-Antagonists / metabolism
  • Adrenergic alpha-Antagonists / pharmacokinetics
  • Adrenergic beta-Antagonists / metabolism
  • Adrenergic beta-Antagonists / pharmacokinetics
  • Adrenergic beta-Antagonists / therapeutic use*
  • Alleles
  • Atenolol / metabolism
  • Benzopyrans / metabolism
  • Biotransformation
  • Bisoprolol / metabolism
  • Carbazoles / blood
  • Carbazoles / metabolism
  • Carbazoles / pharmacokinetics
  • Carvedilol
  • Clinical Trials as Topic
  • Cytochrome P-450 CYP2D6 / genetics*
  • Ethanolamines / metabolism
  • Female
  • Genotype
  • Humans
  • Male
  • Metoprolol / administration & dosage
  • Metoprolol / blood
  • Metoprolol / metabolism
  • Metoprolol / therapeutic use
  • Mutation
  • Nebivolol
  • Pharmacogenetics*
  • Phenotype
  • Polymorphism, Genetic*
  • Propanolamines / blood
  • Propanolamines / metabolism
  • Propanolamines / pharmacokinetics
  • Risk Factors
  • Time Factors

Substances

  • Adrenergic alpha-Antagonists
  • Adrenergic beta-Antagonists
  • Benzopyrans
  • Carbazoles
  • Ethanolamines
  • Propanolamines
  • Nebivolol
  • Carvedilol
  • Atenolol
  • Cytochrome P-450 CYP2D6
  • Metoprolol
  • Bisoprolol